Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rosa Maria Rabanal"'
Autor:
Sandra Guallar-Garrido, Víctor Campo-Pérez, Míriam Pérez-Trujillo, Cecilia Cabrera, Jordi Senserrich, Alejandro Sánchez-Chardi, Rosa Maria Rabanal, Elisabet Gómez-Mora, Estela Noguera-Ortega, Marina Luquin, Esther Julián
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The mechanism of action of intravesical Mycobacterium bovis BCG immunotherapy treatment for bladder cancer is not completely known, leading to misinterpretation of BCG-unresponsive patients, who have scarce further therapeutic options. BCG is grown u
Externí odkaz:
https://doaj.org/article/af55dc8e250440cb82eaa40ce64c7fce
Autor:
Andrea Aran, Vicente Peg, Rosa Maria Rabanal, Cristina Bernadó, Esther Zamora, Elisa Molina, Yago A. Arribas, Joaquín Arribas, José Pérez, Carme Roura-Mir, Montserrat Carrascal, Javier Cortés, Mercè Martí
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
EBV-specific T cells have been recently described to be involved in fatal encephalitis and myocarditis in cancer patients after immune checkpoint therapies. Here, we report the study of a human triple-negative breast cancer tumor (TNBC) and EBV-trans
Externí odkaz:
https://doaj.org/article/d7e27f34772049269cfa3d1b3c5e3466
Autor:
Marc Bach-Griera, Víctor Campo-Pérez, Sandra Barbosa, Sara Traserra, Sandra Guallar-Garrido, Laura Moya-Andérico, Paula Herrero-Abadía, Marina Luquin, Rosa Maria Rabanal, Eduard Torrents, Esther Julián
Publikováno v:
Vaccines, Vol 8, Iss 2, p 198 (2020)
Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On explorin
Externí odkaz:
https://doaj.org/article/faaa4869d01143d39eb9b58ce13d07a3
Autor:
Marta, Caminal, Roberto, Vélez, Rosa Maria, Rabanal, Daniel, Vivas, Laura, Batlle-Morera, Màrius, Aguirre, Jordi, Barquinero, Joan, García, Joaquim, Vives
Publikováno v:
Journal of tissue engineering and regenerative medicine. 11(12)
The use of multipotent mesenchymal stromal cells (MSCs) as candidate medicines for treating a variety of pathologies is based on their qualities as either progenitors for the regeneration of damaged tissue or producers of a number of molecules with p
Autor:
Martí Pumarola Batlle, Rosa Maria Rabanal, Mercè Martí, José Ramón Palacio, Elena Alaños Maite Martínez
Publikováno v:
Universitat Autònoma de Barcelona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3ee638c825f9658d67eb9c47702738ac
https://portalrecerca.uab.cat/en/publications/cd1c3e9b-ad21-4c59-a8d6-d9e832087d77
https://portalrecerca.uab.cat/en/publications/cd1c3e9b-ad21-4c59-a8d6-d9e832087d77
Publikováno v:
Universitat Autònoma de Barcelona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3433dff45906893e05f89e509cbbe5c8
https://portalrecerca.uab.cat/en/publications/421d7edf-0009-4453-a926-94bfbc1a67c5
https://portalrecerca.uab.cat/en/publications/421d7edf-0009-4453-a926-94bfbc1a67c5